Eli Lilly Announces a Diabetes Drug Trial for Children
Recently, Eli Lilly announced that it is planning a clinical trial of its diabetes drug Mounjaro in patients who are six years old or older that have obesity. In fact, according to a United States government registry, Eli Lilly is already underway with a Mounjaro trial on children as young as 10 years old who have type 2 diabetes. Meanwhile, the registry also indicates that the company Novo Nordisk, based in Germany, is also performing a late stage trial of the drug semaglutide, which is sold under the brand name Ozempic in kids who are only 6 years old. Ozempic has been reported to do harm, including gastroparesis. If you or your child is injured as a result of Mounjaro/Ozempic, please call the seasoned Chicago-based trial attorneys of Moll Law Group. We represent children nationwide.
Talk to Moll Law Group About Whether Your Claim is Viable
Both Mounjaro and Ozempic have surged in popularity and demand as treatments for diabetes and obesity. Ozempic is a brand name for semaglutide, which is a medication that manages patients’ blood sugar levels by copying the protein glucagon-like peptide 1 (GLP-1). It lowers your hunger cues and slows digestion in the gut, which can result in weight loss.
More than $1.5 billion in sales were generated by Eli Lilly in the first half of 2023, which is a year after it was approved in the United States. However, it is concerning that children will be subjected to clinical trials because there have been reports that these drugs cause harm, and lawsuits filed in connection with that harm. The Mounjaro lawsuits, which are in their infancy at the time, claim that the drug causes severe gastrointestinal trouble including intestinal blockage and gastroparesis and that Eli Lilly did not adequately inform of the risks associated with taking it.